This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Seattle Genetics Announces Executive Promotions And Management Addition

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced four promotions and an appointment within the company’s commercial and operations teams.

“These staff changes further enable the execution of our goals towards improving the lives of people with cancer,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Chris and Chip have played key roles in the successful launch and ongoing commercialization of ADCETRIS in the United States and Canada. They both have strong backgrounds in oncology drug commercialization, combined with a science-based, patient-oriented approach. Kirk and Mark have been key leaders of the legal group for many years, successfully managing our legal, compliance and intellectual property functions. David brings more than 20 years of leadership experience in the biopharmaceutical industry, including a background in strategic portfolio and program management.”

Chris Boerner, Ph.D., has been promoted to Executive Vice President, Commercial. Dr. Boerner has been with Seattle Genetics for more than three years, serving most recently as Senior Vice President, Commercial. He oversees all sales, marketing and market planning activities for ADCETRIS® (brentuximab vedotin). Prior to Seattle Genetics, he spent more than eight years at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin (bevacizumab) and Director of Avastin franchise management. Additionally, he served in a variety of commercial roles across multiple disease areas, including solid tumor oncology, lymphoma and immunology. Dr. Boerner joined Genentech from McKinsey & Company, a global strategic management consulting firm, where he worked on a variety of pharmaceutical sales and marketing engagements. Dr. Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and his A.B. in Economics and History from Washington University in St. Louis.

Charles (Chip) R. Romp has been promoted to Senior Vice President, Sales. Mr. Romp joined Seattle Genetics in May 2010 to build the company’s field sales organization in advance of the U.S. Food and Drug Administration approval of ADCETRIS. Prior to his promotion to Senior Vice President, he served as Vice President, Sales. Mr. Romp was previously at Genentech, a member of the Roche Group, since 1998, most recently as National Sales Director for Avastin. During his tenure, he held several senior sales leadership positions for both oncology and immunology products, including Rituxan (rituximab) and Xolair (omalizumab), and was project lead for deployment recommendations for Genentech’s BioOncology sales forces. Mr. Romp received his B.A. from the University of Florida and his M.B.A. from Saint Leo University (formerly Saint Leo College) in Florida.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.01 1.05%
FB $99.75 -4.15%
GOOG $682.74 -0.12%
TSLA $147.99 -8.99%
YHOO $27.05 -3.29%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs